Business
Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation
About this update from Prothena Corporation Plc
[{"type":"text","content":"DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated timing for the presentation of results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. As previously announced, results from Part 1 of the Phase 2 PASADENA study of prasinezumab were selected as an oral Top Abstract presentation at the upcoming Virtual 2020 International Congress of Parkinson’s Disease and Movement Disorders Society (MDS Congress). The presentation was previously scheduled for September 14 and will now take place on September 15 in a session on Immunotherapies for Proteinopathies.\n Details for the updated date and time for this oral Top Abstract session are as follows: Session 902: Immunotherapy for ProteinopathiesPASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 resultsPresenter: Gennaro Pagano, MD, MSc, PhD, Senior Principal Medical Director, Translational Medicine, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Pharma Research and Early DevelopmentSession Launch Date and Time: Tuesday, September 15, 2020; 14:30 – 16:30 GMTSession type: Science of Industry (non-CME) A poster regarding PASADENA results will also be included in the Virtual Poster Hall during the MDS Congress. As previously announced, Wagner Zago, PhD, Prothena’s Chief Scientific Officer, will also present as part of this same session. Dr. Zago will speak on the topic of the current status of clinical trials of immunotherapies for the treatment of movement disorders. About Prasinezumab Prasinezumab is a humanized monoclonal antibody under development for the potential treatment of Parkinson's disease. Prasinezumab targets alpha-synuclein and is designed to block the cell-to-cell transmission of the aggregated pathogenic forms of alpha-synuclein in Parkinson's disease, thereby slowing clinical decline. Prior to initiating clinical trials, the efficacy of prasinezumab was evaluated in various cellular and animal models of alpha-synuclein-related disease. In alpha-synuclein transgenic mice, the murine version of prasinezuma...